Almirall, the international pharmaceutical company based in Barcelona, has opened a new subsidiary in Canada. This will be the pharmaceutical’s fourteenth laboratory outside Spain. On the American continent, the company already has a subsidiary in Mexico.
Almirall, owner of medicines such as Almax or Ebastel, will use its Canadian subsidiary primarily to develop therapeutic solutions for respiratory and skin diseases. The new subsidiary, which is based in the city of Mississauga, will also start launching new products aimed at the Canadian domestic market, including a new treatment for chronic obstructive pulmonary disease (COPD) which will hit the shops next autumn.
Posted by flytobarcelona.org; 2013-09-10
Barcelona Air Route Development Committee promotes Barcelona Airport intercontinental